Autoimmune Hepatitis Profiles After Liver Transplantation in Latin American Patients: A Cluster Analysis of Clinical Outcomes
Authors:
- Pedro Robson Costa PassosPPPedro Robson Costa Passos
- Isabel Bastos de MedeirosIMIsabel Bastos de Medeiros
- Tiago Franco DavidTDTiago Franco David
- Mateus Mendes Santos FreireMFMateus Mendes Santos Freire
- Letícia Pinheiro AmorimLALetícia Pinheiro Amorim
- Maria Julya Albuquerque ParenteMPMaria Julya Albuquerque Parente
- Clébia Azevedo de LimaCLClébia Azevedo de Lima
- Antônio Brazil VianaAVAntônio Brazil Viana
- Elodie Bomfim HyppolitoEHElodie Bomfim Hyppolito
- 28 November 2025
- journal article
- Published by Wiley in Hepatology Research
- Vol. 56 (3) , 339-350
Abstract
Aim: Most existing evidence regarding liver transplantation (LT) for autoimmune hepatitis (AIH) originates from European cohorts, hindering the applicability of current guidelines to other populations because of possible geographic variations. There is an urgent need for region‐specific prognostic models. Methods: We analyzed 164 AIH patients from Brazil and Venezuela undergoing LT between 2002 and 2025, the largest AIH LT cohort from Latin America to date. Random survival forests (RSF) identified key predictors of overall survival (OS), graft survival (GS), and AIH recurrence (rAIH). Clustering based on predicted risks identified high‐risk groups with significantly worse outcomes ( p < 0.001 for all). Penalized models with the most important variables from the RSF assessed risk stratification. Results: 5‐, 10‐, and 20‐year OS were 83%, 78%, and 49%. rAIH rates increased from 6% at 5 years to 34% at 20 years. Mycophenolate sodium use in maintenance therapy was ranked as the most important factor for OS (Hazard ratio [HR] = 0.44) and GS (HR = 0.46) prediction, while younger age was the most important risk factor for rAIH. LASSO models accurately predicted early outcomes (1‐year AUCs: OS 0.73, GS 0.73, rAIH 0.81). In a landmark analysis (6 months post‐LT), infectious complications emerged as the main determinant for long‐term OS, and a new model improved 5‐ and 10‐year OS prediction (AUCs: 0.76 and 0.79, respectively). Conclusion: This analysis identifies key predictors that define high‐risk clusters for early and long‐term outcomes in Latin American AIH patients post‐LT, highlighting potential region‐specific factors.Keywords
This publication has 47 references indexed in Scilit:
- Impact of early immunosuppression on pediatric liver transplant outcomes within 1 yearJournal of Pediatric Gastroenterology and Nutrition, 2024
- Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient‐Friendly Summary of the 2019 AASLD GuidelinesClinical Liver Disease, 2021
- Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant RegistryLiver Transplantation, 2020
- Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesHepatology, 2019
- Minimum sample size for developing a multivariable prediction model: PART II ‐ binary and time‐to‐event outcomesStatistics in Medicine, 2018
- Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent diseaseLiver Transplantation, 2015
- Predictors of poor outcome in patients w ith autoimmune hepatitis: A population-based studyHepatology, 2013
- Diagnosis and Management of Autoimmune HepatitisHepatology, 2010
- Risk factors for recurrence of autoimmune hepatitis after liver transplantationLiver Transplantation, 2009
- Simplified criteria for the diagnosis of autoimmune hepatitis†Hepatology, 2008